NetScientific PLC (AIM:NSCI) reported that its portfolio company, PDS Biotechnology Corporation has announced expanded interim data in a Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers.
All patients in the study had failed prior treatment with chemotherapy and 90% had failed radiation treatment, said PDS, a Nasdaq-listed clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, in a statement,
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares leapt higher on Wednesday after the company revealed that the US medical regulator had given the green light for its XENOVIEW drug-device combination product.
The US Food and Drug Administration (FDA) granted approval for XENOVIEW to be used in the evaluation of lung ventilation in adults and children aged 12 and older, the company said, with its scanning software and chest coil devices also given clearance to support a successful launch of the technology into the clinical marketplace.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that Scott Leinenweber has resigned as a non-executive director of the group with immediate effect. The company said its board wished to thank him for his valued contribution during his tenure.
Anglesey Mining PLC (AIM:AYM) has announced that Howard Miller, a non-executive director of the company, passed away on after a short illness on 22 December 2022. Miller had been a non-executive director of Anglesey since 2001, serving as lead independent director from 2013 until his death. On behalf of the board, the company's chairmanJohn Kearney said: “Howard had a wealth of knowledge and experience across all legal, financial and management areas, and provided wise counsel and sound advice to the Anglesey board and company management. We extend our sincere condolences to Howard’s wife, children and family. He will be sadly and fondly missed."
Plexus Holdings PLC (AIM:POS), the AIM-quoted oil and gas engineering services business, has announced that each of the resolutions proposed at the annual general meeting (AGM) were duly passed on a show of hands without a poll of votes being demanded. On 20 October 2022, the company announced that it had raised £1,550,000 through the issue of 1,550,000 convertible loan notes to each of OFM Investment Limited (an entity connected to the van Bilderbeek family), Ben van Bilderbeek, CEO of Plexus, and Jeff Thrall, non-executive director of Plexus, under the terms of a loan note instrument. Following the passing of the resolutions at the AGM, the company is now authorised to enter into the debenture with Ben van Bilderbeek and has done so with effect from the date of the AGM.
Advanced Oncotherapy PLC (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, has announced that, on 23 December 2022, Dr Michael Sinclair, its executive chairman, purchased a total of 80,000 ordinary shares of 25p each in the company at a price of 12.3p per share. Following this purchase, Dr Sinclair has a total beneficial interest in 9,440,814 ordinary shares equivalent to 1.76% of the company's issued share capital.
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said it has received A$800,000 (£450,000) of funding to be used as working capital to fund ongoing operations, including its clinical trials program. The funds were derived from its US$10mln convertible securities financing facility agreed with US institutional fund manager Mercer Street Capital. Under the terms of the facility, the plant-based pharmaceutical company will issue 586,432 convertible notes with a face value of US$1.00 each to Mercer.
Diversified Energy Company PLC (LSE:DEC, OTCQX:DECPF) has appointed Kathryn Klaber as an independent non-executive director, effective 1 January 2023. The appointment is part of its previously announced transition of current board member Melanie Little, maintaining the size of the board at eight members, and diversity composition including 63% independent and 37% female directors. Klaber's 30-plus years of experience has a focus on energy development and environmental, health and safety compliance, with her Klaber Group strategic consulting firm providing services to businesses and organizations with a focus on energy development in the US and abroad.